Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab. and this video is uploaded by VJOncology at 2022-06-06T10:30:45-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [hN101PjDcZk]
| Name | AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 06-06-2022 17:30:45 |
| Video Discription | Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, discusses results of the multi-center, open-label Phase I AMBER (NCT02817633) trial investigating the TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab. Primary endpoints were safety, tolerability, and recommended Phase II dose. 104 patients were included in the trial. The most common cancers were non-small cell lung cancer (NSCLC), skin, and peritoneal mesothelioma. Results demonstrated cobolimab plus dostarlimab were well tolerated and exhibited preliminary antitumor activity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL. [hN101PjDcZk] |
| Category | Education |
| Tags | Speaker: Gerald Steven Falchook | Institution: Sarah Cannon Research Institute at HealthONE | Event: ASCO 2022 | Format: Interview | Subject: General | Field: Treatment | Field: Trial Updates | Trial: AMBER | Medicines: Dostarlimab | Medicines: Cobolimab |
